506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00005982 |
Recruitment Status :
Terminated
(Administratively complete.)
First Posted : January 27, 2003
Last Update Posted : January 23, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome | Drug: nelarabine Other: pharmacological study | Phase 2 |
PRIMARY OBJECTIVES:
I. Determine the response rate, failure-free survival, and progression-free survival of patients with recurrent or refractory cutaneous T-cell lymphoma treated with 506U78.
II. Determine the toxicity of this drug in these patients. III. Study the pharmacokinetics of this drug in these patients.
OUTLINE: This is a multicenter study.
Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients are followed every 6 months.
PROJECTED ACCRUAL: A total of 12-35 patients will be accrued for this study within 3 years.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 35 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study of 506U78 (NSC #686673) in Patients With Previously Treated Cutaneous T-Cell Lymphoma |
Study Start Date : | April 2000 |
Actual Primary Completion Date : | July 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: Treatment (nelarabine)
Patients receive 506U78 IV over 2 hours on days 1, 3, and 5. Treatment continues every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
|
Drug: nelarabine
Given IV
Other Names:
Other: pharmacological study Correlative studies
Other Name: pharmacological studies |
- Response rate (RR) defined as CR + PR rates [ Time Frame: Up to 4 years ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Histologically confirmed relapsed or refractory cutaneous T-cell lymphoma
- Large cell transformation of cutaneous T-cell lymphoma allowed
- No active CNS disease
- Performance status - Zubrod 0-2
- Absolute neutrophil count at least 1,000/mm^3*
- Platelet count at least 100,000/mm^3*
- Bilirubin no greater than 1.5 times upper limit of normal (ULN)
- SGPT no greater than 2.5 times ULN
- Creatinine clearance greater than 50 mL/min
- No history of symptomatic cardiac dysfunction
- No history of pericardial effusion
- HIV negative
- No grade 2 or greater sensory or motor neuropathy
- No history of seizures
- No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin of carcinoma in situ of the cervix
- No medical, psychiatric, or social condition that would preclude study
- No other concurrent serious illness or active infection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior stem cell or bone marrow transplantation (BMT)
- No more than 1 prior immunotherapy regimen
- No more than 3 prior systemic regimens with denileukin diftitox
- At least 3 weeks since prior biologic therapy
- No concurrent BMT
- No prior 506U78
-
No more than 3 prior systemic chemotherapy regimens comprising any of the following:
- Oral methotrexate
- Topical mechlorethamine
- At least 3 weeks since prior chemotherapy
- No other concurrent chemotherapy
- At least 3 weeks since prior anticancer endocrine therapy
- No concurrent topical or systemic steroids
- At least 3 weeks since prior radiotherapy
-
No more than 3 prior systemic regimens comprising any of the following:
- Total skin electron beam therapy
- Spot radiotherapy
-
No more than 3 prior systemic regimens comprising any of the following:
- Oral retinoids
- Ultraviolet therapy (PUVA)
- At least 3 weeks since prior anticancer therapy

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005982
United States, Texas | |
M D Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Andre Goy | M.D. Anderson Cancer Center |
Responsible Party: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00005982 |
Other Study ID Numbers: |
NCI-2012-02344 ID99-213 CDR0000067970 ( Registry Identifier: PDQ (Physician Data Query) ) |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | January 23, 2013 |
Last Verified: | January 2013 |
Mycoses Lymphoma Lymphoma, T-Cell Mycosis Fungoides Sezary Syndrome Lymphoma, T-Cell, Cutaneous Recurrence Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Disease Attributes Pathologic Processes Lymphoma, Non-Hodgkin Bacterial Infections and Mycoses Infections |